Replies to post #256920 on Biotech Values

[dewophile]

The cause-specific HR for the primary endpoint was 0.76, which is not hugely impressive

Isn't it on par w antiplatelet agents, which would make it the preferred option if there is really no increase in bleeding risk whatsoever